Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.

@article{Sears2009LongactingBA,
  title={Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.},
  author={Malcolm R Sears and Anders Ottosson and Finn Radner and Samy Suissa},
  journal={The European respiratory journal},
  year={2009},
  volume={33 1},
  pages={21-32}
}
The safety of long-acting beta(2)-agonist (LABA) treatment in asthma has been questioned following reported increased respiratory deaths when salmeterol was added to usual pharmacotherapy. The aim of this study was to examine whether asthma, cardiac or all-cause mortality and morbidity were increased with formoterol use. The analysis included all AstraZeneca randomised controlled parallel-group asthma trials of 3-12-months duration involving formoterol. Risks associated with formoterol use… CONTINUE READING
48 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

The safety of formoterol among patients with asthma using inhaled corticosteroids

  • R Jaeschke, W Mejza, W Lesniak
  • Am J Respir Crit Care Med
  • 2007

Similar Papers

Loading similar papers…